logo

Arcutis Biotherapeutics Inc. (ARQT)



Trade ARQT now with
  Date
  Headline
9/8/2022 2:22:34 AM Ducentis BioTherapeutics Agrees To Be Acquired By Arcutis Biotherapeutics For Up To $400 Million
8/23/2022 8:28:11 AM Arcutis Completes Enrollment In INTEGUMENT-2 Pivotal Phase 3 Trial Of Ro?umilast Cream In Atopic Dermatitis
7/11/2022 8:19:16 AM Arcutis Biotherapeutics: Health Canada Accepts For Review Roflumilast Cream NDA For Plaque Psoriasis
7/11/2022 8:09:55 AM Arcutis:Health Canada Accepts New Drug Submission For Roflumilast Cream For Adults And Adolescents With Plaque Psoriasis
8/25/2021 8:05:21 AM Arcutis Enrolls First Patient In Phase 3 Clinical Trial Of ARQ-154 As A Potential Treatment For Scalp And Body Psoriasis
8/23/2021 8:12:26 AM Arcutis Biotherapeutics Names Bruce Binkowitz VP Of Biometrics
6/1/2021 7:41:29 AM Arcutis Biotherapeutics Names Rajvir Madan First Chief Digital And Information Officer
2/2/2021 8:54:08 PM Arcutis Biotherapeutics Prices Upsized Public Offering Of 5.50 Mln Shares Of Its Common Stock At $35.00/shr
2/1/2021 7:37:04 AM Arcutis Announces Positive Topline Results From Pivotal DERMIS-1 And -2 Phase 3 Trials Of ARQ-151 In Plaque Psoriasis